Evidence map›Paper›PMID 20842192›Full record

ArticleNature communications2010

Non-muscle myosin II regulates survival threshold of pluripotent stem cells.

Andrea Walker, Hua Su, Mary Anne Conti, Nicole Harb, Robert S Adelstein, Noboru Sato

Open access · bronzeAbstract read
In one paragraph

Article in Nature communications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Temporal and Isoform-Specific Expression ofFrontiers in molecular neuroscience · 2021
    Article
  19. Article
  20. Recapitulating developmental mechanisms for retinal regeneration.Progress in retinal and eye research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Andrea WalkerDepartment of Biochemistry, University of California, Riverside, Riverside, California 29521, USA.
Hua Su
Mary Anne Conti
Nicole Harb
Robert S Adelstein
Noboru Sato
University of California, Riverside · USNational Heart Lung and Blood Institute · US

Funding

In Vivo Function of Nonmuscle Myosin II-AZIAHL004218 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ADELSTEIN, ROBERT · 2009 to 2019
$5.1M
In Vivo Function of Nonmuscle Myosin II-AZ01HL004218 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ADELSTEIN, ROBERT · 1991 to 2008
$826k
Intramural NIH HHS Z01 HL004218
6 · The paper itself

Abstract

Human pluripotent stem (hPS) cells such as human embryonic stem (hES) and induced pluripotent stem (hiPS) cells are vulnerable under single cell conditions, which hampers practical applications; yet, the mechanisms underlying this cell death remain elusive. In this paper, we demonstrate that treatment with a specific inhibitor of non-muscle myosin II (NMII), blebbistatin, enhances the survival of hPS cells under clonal density and suspension conditions, and, in combination with a synthetic matrix, supports a fully defined environment for self-renewal. Consistent with this, genetically engineered mouse embryonic stem cells lacking an isoform of NMII heavy chain (NMHCII), or hES cells expressing a short hairpin RNA to knock down NMHCII, show greater viability than controls. Moreover, NMII inhibition increases the expression of self-renewal regulators Oct3/4 and Nanog, suggesting a mechanistic connection between NMII and self-renewal. These results underscore the importance of the molecular motor, NMII, as a novel target for chemically engineering the survival and self-renewal of hPS cells.

Indexed as

AnimalsCell LineCell SurvivalEmbryonic Stem CellsGenetic VectorsHeterocyclic Compounds, 4 or More RingsHumansIn Situ Nick-End LabelingKaryotypingLentivirusMiceMyosin Type IIPluripotent Stem CellsRNA, Small InterferingblebbistatinHeterocyclic Compounds, 4 or More RingsMyosin Type IIRNA, Small Interfering

Identifiers

PMID20842192
PMCPMC3430968
OpenAlexW2068811666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.